Im­ple­ment­ing 'Right-to-Try': FDA sig­nals like­li­hood of on­ly min­i­mal man­u­fac­tur­er par­tic­i­pa­tion

When for­mer Pres­i­dent Don­ald Trump signed the Right to Try Act in­to law in May 2018, both he and for­mer VP Mike Pence called the law his­toric, pledg­ing that it would open up ac­cess to all sorts of new “life-sav­ing” drugs for those with ter­mi­nal ill­ness­es and few op­tions.

“A lot of that try­ing is go­ing to be suc­cess­ful, I re­al­ly be­lieve it,” Trump said at the time.

But in the four years since the law was en­act­ed, the num­ber of new pa­tients treat­ed and the mag­ni­tude of the ben­e­fit from that ear­ly ac­cess re­mains en­tire­ly un­known.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER